Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
The purpose of this work was to carry out preclinical toxicity and bio-distribution studies required for regulatory approval of a clinical trial application for Phase I clinical studies of ONCOS-102 (Ad5/3-D24-GM-CSF) for therapy of advanced cancers (NCT01598129). The study design, route of administ...
Main Authors: | Lukasz Kuryk, Lotta Vassilev, Tuuli Ranki, Akseli Hemminki, Aila Karioja-Kallio, Onerva Levälampi, Antti Vuolanto, Vincenzo Cerullo, Sari Pesonen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0182715&type=printable |
Similar Items
-
Oncolytic Immunotherapy: Where Are We Clinically?
by: Akseli Hemminki
Published: (2014-01-01) -
Oncolytic adenovirus inhibits TNBC tumor growth/metastasis in mice by targeting TGFB and overexpressing GM-CSF
by: Nguyễn Thị Thanh Nhàn, et al.
Published: (2025-03-01) -
Immune Evasion of G-CSF and GM-CSF in Lung Cancer
by: Yeonhee Park, et al.
Published: (2024-01-01) -
Ad6-Based GM-CSF Expressing Vector Displays Oncolytic and Immunostimulatory Effects in an Immunocompetent Syrian Hamster Model of Cholangiocarcinoma
by: Daria S. Zabelina, et al.
Published: (2025-01-01) -
Development of Dendritic Cells from GM-CSF-/-Mice invitro : GM-CSF Enhances Productionand Survival of Cells
by: Keping Ni, et al.
Published: (2001-01-01)